Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Health and Human Services Secretary Robert F. Kennedy Jr. misrepresented the country’s compensation program for those who are ...

The Philadelphia College of Pharmacy was the first pharmacy college in North America. And for 30 years, the historic ...

Britain’s cash-strapped Labour government cannot fold to every corporate lobbying campaign. But it ought to heed Soriot and ...

Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...

Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as ...

Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.